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Background: The aim of the trial was to compare two active adjuvant chemotherapy regimens in patients with
early stage colorectal cancer (CRC).
Methods: Patients were assigned to oxaliplatin, leucovorin and 5-FU for 12 cycles (group A, FOLFOX6) or oxaliplatin
and capecitabine for eight cycles (group B, CAPOX). Primary endpoint was disease-free survival (DFS). Tumors were
classified as mismatch repair proficient (pMMR) or deficient (dMMR) according to MLH1, PMS2, MSH2 and MSH6 protein
expression. KRAS exon two and BRAF V600E mutational status were also assessed.
Results: Between 2005 and 2008, 441 patients were enrolled, with 408 patients being eligible. After a median follow-up
of 74.7 months, 3-year DFS was 79.8 % (95 % CI 76.5–83.4) in the FOLFOX group and 79.5 % (95 % CI 75.9–83.1) in the
CAPOX group (p = 0.78). Three-year OS was 87.2 % (95 % CI 84.1-91.1) in the FOLFOX and 86.9 % (95 % CI 83.4–89.9) in
the CAPOX group (p = 0.84). Among 306 available tumors, 11.0 % were dMMR, 34.0 % KRAS mutant and 4.9 % BRAF
mutant. Multivariate analysis showed that primary site in the left colon, earlier TNM stage and the presence of anemia
at diagnosis were associated with better DFS and overall survival (OS), while grade one–two tumors were associated
with better OS. Finally, a statistically significant interaction was detected between the primary site and MMR status
(p = 0.010), while KRAS mutated tumors were associated with shorter DFS. However, the sample was too small for
safe conclusions.
Conclusions: No significant differences were observed in the efficacy of FOLFOX versus CAPOX as adjuvant treatment
in high-risk stage II or stage III CRC patients, but definitive conclusions cannot be drawn because of the small sample size.
Trial registration: ANZCTR 12610000509066. Date of Registration: June 21, 2010.
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Colorectal cancer (CRC) is the third most common ma-
lignancy and the third leading cause of cancer death in
the US [1]. Approximately half of the patients diagnosed
with colorectal cancer will be cured after surgery and
adjuvant treatment, while the rest will die from meta-
static disease [2]. The role of adjuvant chemotherapy in
stage III colon cancer is well established, according to
several landmark randomized phase III trials. It has been
shown that it reduces the risk of recurrence by 19–40 %
and the risk of death by 16–33 % [3]. However, the role of
adjuvant chemotherapy in patients with operated stage II
colon cancer has not been clearly defined as yet. Current
guidelines suggest the administration of adjuvant chemo-
therapy in stage II colon cancer patients when high-risk
clinicopathological features are present [4].
The combination of oxaliplatin with leucovorin and
bolus/infusional 5-fluorouracil (5-FU), called FOLFOX4, is
the best-studied regimen in colorectal cancer and has
proven its beneficial role as adjuvant chemotherapy [3, 5].
However, this regimen has in fact been replaced by modi-
fied FOLFOX6 (mFOLFOX6), which can be easily adminis-
tered by a central venous catheter, avoiding hospitalization,
and is accepted as equally effective as FOLFOX4 by the
oncologic community. Capecitabine is an orally adminis-
tered fluoropyrimidine prodrug that is biotransformed
into active metabolites within cancer cells and mimics 5-
FU infusion when it is administered twice daily. Capecita-
bine showed similar efficacy compared to bolus 5-FU/LV
as adjuvant treatment in the X-ACT clinical trial [6],
whereas its combination with oxaliplatin (CAPOX) dem-
onstrated improved disease-free survival rate compared to
bolus 5-FU/LV [7]. However, as far as we know, a formal
comparison between CAPOX and FOLFOX in the adju-
vant setting, in the context of a randomized trial, has
never been performed.
The primary objective of the present prospective ran-
domized clinical trial was to compare 3-year disease-free
survival (DFS) rates between the two treatment schedules,
mFOLFOX6 to the combination of oxaliplatin and cape-
citabine (CAPOX). Secondary endpoints were 3-year over-
all survival (OS) rates and the toxicity profile of therapies
administered. An exploratory objective was the study of
clinicopathological characteristics and biomarkers for po-
tential prognostic and predictive utility.
Methods
Patients
In this multicenter prospective randomized phase III trial,
patients with completely resected high-risk early stage
CRC were enrolled. All patients had histologically con-
firmed high-risk American Joint Committee on Cancer
(AJCC) stage II or stage III CRC. According to the proto-
col, high-risk features for stage II disease were highhistological grade, lymphovascular or perineural invasion,
mucinous component, T4 stage, extramural vein invasion,
symptomatic bowel obstruction or perforation at diagnosis
and less than 12 lymph nodes removed. Surgical resection
with no residual disease should have been performed 4–8
weeks before enrollment, while adequate performance sta-
tus (PS 0–1) and organ function had been confirmed. Ex-
clusion criteria were the presence or history of malignant
tumors, other than non-melanoma cancer of the skin and
in-situ cervical cancer, severe cardiac disease, uncontrolled
metabolic disorders or serious uncontrolled active infection,
inflammatory bowel disease, loss of proximal gastrointes-
tinal tract integrity, malabsorption syndrome, current his-
tory of chronic diarrhea, gastrointestinal hemorrhage or
peptic ulcer, other serious concomitant diseases and a com-
promised general condition, including major neurological
and psychiatric disorders, pregnancy or breastfeeding.
Treatment
Patients were randomly assigned to receive oxaliplatin
85 mg/m2 on day 1, leucovorin 200 mg/m2 as a 2-h infu-
sion on day 1 and 5-FU 400 mg/m2 IV bolus on day 1
followed by a 5-FU 2,400 mg/m2 46-h continuous infu-
sion, repeated every 14 days for 12 cycles (group A,
modified [m]FOLFOX6) or oxaliplatin 130 mg/m2 on
day 1 and capecitabine (Xeloda®) 1,000 mg/m2 bid on
days 1–14, repeated every 21 days for eight cycles (group
B, CAPOX). During randomization, done centrally at
the Hellenic Cooperative Oncology Group (HeCOG)
data office, patients were stratified according to the
AJCC stage (high-risk II versus III). All patients with
rectal primaries received adjuvant radiotherapy 46 Gy to
the pelvic area and a 4 Gy boost, for a total dose of 50
Gy, concomitantly with capecitabine 825 mg/m2 twice
daily on the days of radiotherapy, according to the exist-
ing local guidelines at that time. Two cycles of chemo-
therapy were administered before and the rest, 10 cycles
for mFOLFOX6 or six cycles for CAPOX, after the com-
pletion of chemoradiotherapy.
All adverse events were recorded according to the
National Cancer Institute Common Toxicity Criteria
(NCI CTC) version 2.0 grading scale. The first cycle
was administered according to the inclusion criteria de-
scribed above. Subsequent cycles were not administered
unless the granulocyte number was ≥1,500/mm3, platelet
number ≥100,000/mm3 and all non-hematological toxic-
ities resolved to grade ≤1. In case of a 2-week delay, treat-
ment could be interrupted, according to the investigator’s
decision. Capecitabine was interrupted in case of hand-
foot syndrome, mucositis or diarrhea grade two, until
these toxicities were resolved. The capecitabine doses that
had been omitted were not given at a later point. Admin-
istration of G-CSF and recombinant erythropoietin was
allowed. Also, oral pyridoxine was allowed, administered
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syndrome. Finally, oxaliplatin was permanently inter-
rupted in case of neurotoxicity grade ≥3.
Evaluation of disease
Follow-up evaluation for disease recurrence was carried out
after the completion of treatment in all patients, every 3
months for the first year, every 4 months for the second and
third year and every 6 months for the fourth and fifth year,
by serum carcinoembryonic antigen (CEA), chest X-rays
and computed tomography (CT) scans of the abdomen and
pelvis. Chest CT scans and MRI or bone scans were allowed
when indicated.
The clinical protocol was approved by Institutional
Review Boards (IRBs) in participating institutions (shown
in Additional file 1: Table S1) and by the National
Organization for Medicines. The trial was included in the
Australian New Zealand Clinical Trials Registry on the
21st of June 2010 and allocated the following Registration
Number: ANZCTR 12610000509066. Written informed
consent for participation in the trial was obtained from all
the patients and optionally a separate informed consent
was obtained for providing biological material for research
purposes.
KRAS and BRAF genotyping
A total of 328 formalin-fixed paraffin-embedded tumor
tissue samples were processed for tissue microarray
(TMA) construction with the Alpheys Minicore 3 Tissue
Microarray system (Plaisir, France). For each case, three
tumor and, where possible, three normal 1mm cores
were embedded into the recipient block.
Upon histological evaluation, 319 tumors were avail-
able for DNA extraction from 8 um TMA core sections
with >30 % tumor cell content. Following deparaffiniza-
tion, the VERSANT Sample 1.0 Reagent Kit (Siemens
Healthcare Diagnostics, Tarrytown, NY) was used for
magnetic beads DNA isolation, according to the manu-
facturer’s instructions. Genotyping was performed with
dd-sequencing on nested PCR products with intronic
primers spanning the entire exons of interest, as follows:
KRAS exon 2, 1st PCR forward 5′-CGTCTGCAGTCAAC
TGGAATTT-3′ and reverse 5′-TTACTGGTGCAGGACC
ATTCTTT-3′; nested forward 5′-TTTAACCTTATGTG
TGACATGTTCTAA-3′ and reverse 5′-GCATATTACTG
GTGCAGGACCA-3′.
BRAF exon 15, 1st PCR forward 5′-ATAATGCTTGCTC
TGATAGG-3′ and reverse 5′-GTGAATACTGGGAACTAT
GAA-3′; nested forward 5′-CTACTGTTTTCCTTTACTTA
C-3′ and reverse 5′-GGGAACTATGAAAATACTATA-3′.
Nested primers were 5′-end M13 coupled. Sense and
antisense sequencing was performed using M13 forward
and reverse primers in 10 ul reactions with the Big Dye
Terminator kit v.1.1 (Applied Biosystems/Life Technologies,Paisley, UK). Products were visualized upon capillary elec-
trophoresis in an ABI3130XL genetic analyzer, base called
and further analyzed with the Sequencing Analysis version
5.2 software (Applied Biosystems). A total of 307 tumors
were informative for KRAS exon 2 and BRAF exon 15
mutation status (96.2 %).
Mismatch repair (MMR) protein immunohistochemistry (IHC)
IHC was carried out on 2 um thick TMA sections with
the following antibodies and conditions: MLH1, clone
ES05 (Monosan, Uden, Netherlands) at 1:80 dilution;
MSH2, clone 25D12 (Novocastra/Leica Microsystems,
Wetzlar, Germany) at 1:40 dilution; MSH6, clone EP49
(DAKO, Glostrup, Denmark) at 1:60 dilution; and,
PMS2, clone M0R4G (Novocastra/Leica Microsystems)
at 1:50 dilution. All tests were performed using a Bond
Max™ autostainer (Leica Microsystems) with diamino-
benzidine as chromogen for protein-antibody complex
visualization. Stains were evaluated by two pathologists
(G.R. and E.V.) for all tumor and normal cores, along with
external controls for assessing method performance. Each
core was evaluated for nuclear staining intensity and distri-
bution of positive cells at 200× and 400× [8]. Tumors were
scored for (a) the incidence of positive cells as 0 (<10 %
positive), 1 (10–30 % positive), 2 (30–70 % positive) and 3
(>70 % positive); and (b) for staining intensity as 0 (nega-
tive), 1 (mild), 2 (intermediate) and 3 (strong), in compari-
son to internal controls (lymphocytes, normal epithelia)
[9–11]. Scores for each core were recorded. For the pur-
poses of the present study, tumors were classified as posi-
tive for incidence and intensity categories 1–3 (≥10 %
positive nuclei with mild to strong intensity).
Statistical analysis
The design was that of a superiority trial. A sample of 800
patients was required for the study, to ensure an 80 %
power at the 5 % level of significance, for a two-sided test
of the hypothesis that a difference of ±5 % in 3-year DFS
rate exists from a baseline 3-year DFS rate of 78.2 %.
Considering a 3 % withdrawal rate, 824 patients needed
to enter the study. An interim analysis based on the
O’Brien Fleming boundary values was planned when half
(50 %) of the DFS events (166 relapses) had been
reached. The study would be ended prematurely if either
a significant difference was detected or the alternative
hypothesis was rejected at the interim analysis.
Enrollment was closed prematurely at 441 patients be-
cause of slow accrual. At the time of the analysis, a futil-
ity test was retrospectively undertaken showing that,
even if the study was to continue recruitment to reach
the pre-specified number of 824 patients, the probability
of reaching the primary endpoint, considering the 3-year
DFS as it was defined by the study design, would not
have been more than 0.1.
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the corresponding range and categorical variables as
frequencies with the respective percentages. Chi-square
or Fisher’s exact tests and the non-parametric Mann–
Whitney test were used for comparing patient and tumor
characteristics.
OS was measured from the date of randomization to
the date of patient’s death or last contact, while DFS was
measured from the date of randomization to docu-
mented first recurrence, death without prior docu-
mented recurrence or last contact, whichever occurred
first. Surviving patients were censored at the date of last
contact. Time to event distributions were estimated
using Kaplan-Meier curves and compared using log-rank
tests. For all univariate tests, significance level was set at
α = 0.05. Cox proportional hazards models were used to
assess the relationship of OS and DFS with various clinical
and histological variables. Concerning multivariate ana-
lyses, significance threshold for keeping a variable in the
final model was set at α = 0.15. The following standard pa-
rameters were included in the multivariate analyses: age,
gender, primary site, stage and anemia. Treatment groups,
as well as the examined markers, were included in the final
model, in order to determine whether they added inde-
pendent prognostic information to the model containing
the significant clinicopathological parameters. No adjust-
ments for multiple comparisons were done. Analyses of
survival parameters and objective response rates were per-
formed in all randomized patients (intention to treat, ITT
population), while analyses of toxicity and therapy charac-
teristics were performed only in patients who did receive
treatment (treated patient population).
The SAS software was used for statistical analysis (SAS
for Windows, version 9.3, SAS Institute Inc., Cary, NC).
Results
Between November 2005 and January 2008, 441 pa-
tients were enrolled in the study. Among them, 408 pa-
tients (92.5 %) were eligible, with 197 randomized to
group A (mFOLFOX6) and 211 to group B (CAPOX).
The CONSORT diagram for the patient population is
shown in Fig. 1. Table 1 shows the baseline characteristics
of all eligible patients. The two groups of patients were
balanced in selected patient and disease characteristics.
Treatment
In total, 196 patients received 2,022 cycles of mFOLFOX6
(median, 12; range, 1–12) and 207 patients received 1,372
cycles of CAPOX (median, 8; range, 1–8). Among
them, 146 patients (74.1 %) completed treatment with
mFOLFOX6 and 128 (61.0 %) with CAPOX. In total, in
the mFOLFOX6 group (group A), 47 patients (23.4 %)
and 51 (25.4 %) required a dose reduction of oxaliplatin
and 5-FU, respectively. In the CAPOX group (group B), 8patients (3.8 %) and 130 (61.0 %) required a dose reduction
of oxaliplatin and capecitabine, respectively. Median rela-
tive dose intensities in the mFOLFOX6-treated patients
were 98.8 % (range, 13–100 %) for oxaliplatin, 99.7 %
(range, 42–100 %) for bolus 5-FU and 99.5 % (range,
43–100 %) for the continuous infusion 5-FU, while in
the CAPOX-treated patients dose intensities were
99.3 % (range, 19–100 %) for oxaliplatin and 82.8 %
(range, 29–100 %) for capecitabine.
Toxicity
Adverse events of all grades, seen in ≥5 % of the pa-
tients, are shown in Table 2. The most common grade
three–four toxicities were neutropenia (26.9 % of pa-
tients with mFOLFOX6 versus [vs] 8.1 % with CAPOX,
p < 0.0002) and sensory neuropathy (7.1 % of patients
with mFOLFOX6 vs 4.3 % with CAPOX, p = 0.21).
Vomiting was more frequent in the CAPOX group (1.57
% vs 0 %, p = 0.012). Other severe toxicities with different
incidences between the two arms were diarrhea (4.0 % of
patients with mFOLFOX6 vs 7.1 % with CAPOX, p = 0.18)
and fatigue (1.0 % of patients with mFOLFOX6 vs 2.4 %
with CAPOX, p = 0.23).
Survival
After a median follow-up of 74.7 months (range 0–155.5
months), 54 patients (27.4 %) relapsed and 43 (21.8 %)
died in the mFOLFOX6 group, while 61 patients (28.9 %)
relapsed and 45 (21.3 %) died in the CAPOX group.
Median DFS has not been reached for both groups, while
3-year DFS was 79.8 % (95 % confidence intervals [CI]
76.5–83.4) in the mFOLFOX6 group and 79.5 % (95 % CI
75.9–83.1) in the CAPOX group (p = 0.784). Median OS
has also not been reached in both groups, while 3-year OS
was 87.2 % (95 % CI 84.1–91.1) in the mFOLFOX6
group and 86.9 % (95 % CI 83.4–89.9) in the CAPOX
group (p = 0.844). Kaplan-Meier curves for OS and DFS
according to treatment are shown in Fig. 2. Overall, no
significant survival differences were seen between the two
treatment arms for either DFS or OS (mFOLFOX6 vs
XELOX: Hazard ratio [HR] = 0.91, 95 % Confidence Inter-
vals [CI] 0.58–1.44 and HR = 1.05, 95 % CI 0.68–1.60,
respectively).
MMR protein status and KRAS-BRAF mutations
Tumors were classified, according to IHC positivity for
MLH1, PMS2, MSH2 and MSH6, in MMR proficient
(pMMR) if all proteins were expressed and MMR defi-
cient (dMMR) in case of null expression of at least one
protein. Among 309 tumors informative for all MMR
proteins, 34 (11.0 %) were dMMR and 275 (89.0 %) were
pMMR. dMMR status was associated with absence of
expression of MLH1 and/or PMS2 in 13 cases (38 %)
and of MSH2 and/or MSH6 in 20 cases (59 %), while in
Fig. 1 CONSORT diagram
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associated with higher grade and mucinous component
in histology, while anemia was associated with earlier
clinical stage (16.5 % for stage II versus 7.3 % for stage
III, p = 0.014). Also, there was a trend for higher fre-
quency of dMMR tumors in the right than in the left
colon (p = 0.135) and in older patients (p = 0.08).
Among 307 tumors informative for BRAF and KRAS sta-
tus, 15 (4.9 %) carried the V600E BRAF mutation, while
104 (34.0 %) were found to be KRAS mutants. Ninety-four
tumors had codon 12 mutations (74 G12D, 7 G12C, 6
G12V, 4 G12S, 2 G12A and 1 G12R) and 10 had codon
G13D mutations. No associations were noticed between
mutations and basic patient or disease characteristics. KRAS
and BRAF mutations were mutually exclusive. Also, KRAS
or BRAF mutations were not associated with MMR status.
Prognostic factor analysis
In univariate analysis, earlier AJCC clinical stage II versus
III was associated with longer DFS (3-year DFS 92.0 % vs73.8 %, respectively, HR = 0.31, 95 % CI 0.17–0.58, Wald’s
p < 0.001) and OS (3-year OS 95.2 % vs 84.0 %, respect-
ively, HR = 0.24, 95 % CI 0.12–0.47, p < 0.001), primary
tumor location in the left colon with better OS (3-year OS
90.4 % vs 79.4 %, HR = 0.59, 95 % CI 0.38–0.91, p = 0.011)
and anemia at the time of diagnosis with longer DFS
(3-year DFS 85.2 % vs 78.1 %, HR = 0.29, 95 % CI 0.13–
0.68, p = 0.008). Also, within stage III, patients with N2
disease had worse DFS (HR = 2.29, 95 % CI 1.53–3.44, p <
0.001) and OS (HR = 3.26, 95 % CI 2.01–5.29, p < 0.001)
than those with N1. No conclusions could be made for
T4N0 patients because their number was very low. Ex-
ploratory subgroup analysis showed that mutated KRAS
was associated with shorter DFS in the subset of patients
with left colon primary tumors (HR = 2.30, 95 % CI 1.17–
4.52, p = 0.020) or stage II disease (HR = 1.88, 95 % CI
1.17–3.02, p = 0.010). In the group of rectal cancer pa-
tients, low rectal primary tumor location (first 5 cm from
anal sphincter) was associated with worse DFS (3-year DFS
68.8 % vs 87.1 %, HR = 2.02, 95 %CI 1.27–5.31, p = 0.016)
Table 1 Patient and disease characteristics
Group A Group B p-value
N = 197 N = 211
Age Median 62.4 63.7 0.45
Range 23.7–74.7 36.6–75.0
BMI Median 26.75 26.90 0.89
Range 17.9–34.6 17.3–35.0
N (%) N (%)
Gender Female 86 (43.6) 94 (44.5) 0.91
Male 111 (56.4) 117 (55.5)
PS (ECOG) 0 177 (91.7) 195 (93.7) 0.37
1 16 (8.3) 13 (6.3)
Unknown 4 3
Anemia (Hb < 12g/dL) No 148 (77.9) 161 (78.9) 0.75
Yes 42 (22.1) 43 (21.1)
Unknown 7 7
Weight loss No 181 (94.8) 191 (93.6) 0.61
Yes 10 (5.2) 13 (6.4)
Unknown 6 7
TNM stage II 61 (31.9) 68 (33.5) 0.66
T3N0 54 (88.5) 60 (88.2)
T4N0 7 (11.5) 8 (11.8)
III 130 (68.1) 135 (66.5)
TxN1 81 (62.3) 83 (61.5)
TxN2 49 (37.7) 52 (38.5)
Unknown 6 8
Histological grade Grade 1 12 (6.3) 12 (5.9) 0.82
Grade 2 139 (72.4) 152 (74.9)
Grade 3 41 (21.3) 39 (19.2)
Unknown 5 8
Mucinous component No 120 (67.8) 128 (72.7) 0.35
Yes 57 (32.2) 48 (27.3)
Unknown 20 35
Obstruction No 167 (85.2) 179 (86.1) 0.84
Yes 29 (14.8) 29 (13.9)
Unknown 1 3
Perforation No 181 (92.0) 190 (91.8) 0.95
Yes 16 (8.0) 17 (8.2)
Unknown 0 4
LVI/PNI (stage II)a No 48 (80.0) 57 (85.1) 0.45
Yes 12 (20.0) 10 (14.9)
Unknown 1 1
Table 1 Patient and disease characteristics (Continued)
Primary site Right colonb 58 (29.5) 64 (30.8) 0.89
Left colonb 86 (43.6 %) 87 (41.8 %)
Rectum 53 (26.9 %) 57 (27.4 %)
Unknown 0 3
BMI body mass index, PS performance status, Hb hemoglobin; Tx any T
aLymphovascular and/or perineural infiltration in patients with stage II disease
bRight colon: cecum, ascending colon, hepatic flexure, transverse colon; Left
colon: splenic flexure, descending colon, sigmoid
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1.19–5.31, p = 0.024) compared to middle (>5–10 cm) and
upper (>10 cm) rectal tumors. Regarding the impact on
DFS/OS, no significant interactions were observed be-
tween the treatment arm (FOLFOX or CAPOX) and any
of the clinicopathological or molecular characteristics
under study.
Multivariate analysis of prognostic factors showed that
earlier TNM stage and the presence of anemia at diagno-
sis were associated with better DFS (HR = 0.31, 95 % CI
0.16–0.66, p = 0.002 and HR = 0.29, 95 % CI 0.12–0.67,
p = 0.007, respectively) and OS (HR = 0.06, 95 % CI 0.02–
0.26, p < 0.001 and HR = 0.41, 95 %CI 0.18–0.93, p = 0.035,
respectively) (Fig. 3). Also, primary site location in the
right colon was associated with worse DFS (HR = 1.79,
95 % CI 1.14–3.37, p = 0.010), while lower histological
grade tumors were associated with better OS (HR = 0.43,
95 % CI 0.20–0.92, p = 0.031). Finally, dMMR was associ-
ated with shorter OS only in the left colon (p = 0.010 for
interaction), as shown in Fig. 3, while mutated KRAS was
associated with shorter DFS in the subset of patients with
left colon tumors (HR = 2.30, 95 %CI 1.17–4.52, p = 0.020),
but not in those with stage II disease.
Discussion
In the present trial, patients with high-risk stage II or stage
III surgically removed colorectal cancer were randomized
between mFOLFOX6 and CAPOX, which are two estab-
lished adjuvant chemotherapy regimens. FOLFOX has
demonstrated its superiority over infusional 5-FU/LV in
patients with stage III disease in the MOSAIC trial, with a
5-year DFS of 66.4 % and 6-year OS of 72.9 % [5]. Also,
CAPOX was found superior to infusional 5-FU/LV in pa-
tients with stage III colon cancer with 3-year DFS reach-
ing 70.9 % [7].
Our study demonstrated rather similar efficacy of the
two regimens, with 3-year DFS and OS reaching 79.8 %
and 87.2 %, respectively in the mFOLFOX6 group and
79.5 % and 86.9 %, respectively in the CAPOX group.
Although the planned accrual was not achieved, retro-
spective futility analysis showed that superiority would
have unlikely been shown in the case of completion.
Also, this trial was not designed to demonstrate non-
inferiority, while the inclusion of stage II patients might
Table 2 Toxicities by maximum NCI CTC version 2.0 grade




1 2 3 4 1 2 3 4
Hemoglobin N 115 10 1 . 105 21 2 .
% 58.4 5.1 0.5 . 49.7 9.9 0.9 .
Leucocytes N 65 60 5 . 77 35 5 .
% 33.0 30.4 2.5 . 36.5 16.6 2.4 .
Neutrophils N 22 57 40 13 61 48 16 1
% 11.2 28.9 20.3 6.6 28.9 22.7 7.6 0.5
Febrile neutropenia N 1 . . . . . 2 .
% 0.5 . . . . . 0.9 .
Platelets N 75 26 5 . 70 32 7 .
% 38.1 13.2 2.5 33.2 15.2 3.31 .
Nausea N 34 9 2 . 36 13 3 .
% 17.3 4.6 1.0 17.1 6.2 1.4
Vomiting N 17 14 . . 19 13 5 1
% 8.6 7.1 9.0 6.2 2.4 0.5
Mucositis N 9 3 2 . 4 1 . .
% 4.6 1.5 1.0 1.9 0.5
Diarrhea N 26 12 6 2 27 28 12 3
% 13.2 6.1 3.0 1.0 12.8 13.0 5.7 1.4
Constipation N 19 4 . . 15 5 . .
% 9.6 2.0 7.6 2.4
Liver toxicity N 71 17 2 . 69 7 . .
% 36.0 8.6 1.0 32.7 3.3
Neuropathy N 59 43 14 . 66 44 9 .
% 29.9 21.8 7.1 31.2 20.8 4.3
HandFoot N 4 1 . . 10 3 1 .
% 2.1 0.5 4.7 1.4 0.5
Alopecia N 6 2 . . 2 1 . .
% 3.0 1.0 0.9 0.5
Allergic reaction N 4 9 2 . 5 1 4 .
% 2.0 4.6 1.0 2.4 0.5 1.9
Fever N 9 5 . . 13 3 . .
% 4.6 2.5 6.2 1.4
Infection N . 4 1 . . 4 1 .
% . 2.0 0.5 1.9 0.5
Fatigue N 23 7 2 . 28 8 4 1
% 11.6 3.6 1.0 13.2 3.8 1.9 0.5
Dizzines N 6 1 . . 8 . . .
Table 2 Toxicities by maximum NCI CTC version 2.0 grade
for each treatment arm (N, number of patients)
(Continued)
% 3.0 0.5 3.8
Musculoskeletal pain N 5 2 . . 7 2 . .
% 2.5 1.0 3.3 0.9
Metabolic N 18 . . . 17 2 . .
% 9.1 8.1 0.9
NCI CTC National Cancer Institute Common Toxicity Criteria
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small differences, if any, in the efficacy of the two stand-
ard regimens. Nevertheless, this study contributes to the
knowledge drawn from other trials that CAPOX is an
acceptable regimen for the adjuvant treatment of colon
cancer. One of them, the recently published AVANT
trial [12], showed no difference between FOLFOX4 and
CAPOX-bevacizumab in a much larger population, al-
though it cannot be excluded that bevacizumab might
have influenced the results. The only differences we
could show between the two regimens were the neces-
sity for placement of a central venous catheter for
mFOLFOX6 and the distinct toxicity profile, with neu-
tropenia appearing more frequently with mFOLFOX6
and vomiting with CAPOX. However, long-term toxicity,
which is almost entirely represented by neuropathy, was
nearly equally distributed between the two groups.
Therefore, the choice between mFOLFOX6 and CAPOX
should be discussed and guided according to doctors’
decisions and patients’ preferences.
The indication and choice of adjuvant chemotherapy
in patients with stage II colon cancer have not been
clarified as yet. Most trials showed no benefit in terms
of DFS and OS and only the QUASAR study demon-
strated a 29 % reduction in the risk for relapse at 2 years
with adjuvant 5-FU/LV compared to observation [13].
Also, a recent meta-analysis showed that adjuvant
chemotherapy offered a DFS and OS advantage in pa-
tients with stage II colon cancer, but the chemotherapy
regimens were not all standard and the quality of the
surgery was not always the best [14]. Therefore, current
guidelines suggest adjuvant chemotherapy as an option
in patients with stage II disease and high-risk features,
such as grade 3 histology, vascular/lymphatic invasion,
bowel obstruction or perforation, T4 primary with close,
indeterminate or positive surgical margins, and low
quality of surgery (less than 12 regional lymph nodes re-
moved), according to a pooled analysis of seven random-
ized trials [15]. These data justify our decision to include
patients with high-risk stage II colorectal cancer in our
trial, though the regimen selection is still not adequately
established. A post-hoc analysis of NSABP C-07 data
[16], which was published after the completion of the
Fig. 2 Survival curves for disease-free survival and overall survival in the two treatment arms. Shaded areas represent 95 % Hall-Wellner bands
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was improved by the addition of oxaliplatin to 5-FU/LV
in patients with operated stage II colon cancer.
Recent progress in preclinical and translational re-
search has shed light on multiple aspects of the molecu-
lar biology of colon cancer. Several lines of evidence
confirmed the classification of colon cancer in two major
groups; one characterized by chromosomal instability
(CIN) and another harboring defects in mismatch repair
enzymes (dMMR) leading to a hypermutated phenotype,
otherwise called microsatellite instability (MSI). These
defects are attributed either to germline mutations of
the MMR enzymes (Lynch syndrome) or to acquired
methylation of the promoter region of the MLH1 gene
[17]. The present study, in accordance to what has
already been shown in the literature [18], showed thatdMMR was more often associated with older age, earlier
clinical stage and right-sided colon tumors of mucinous
or high-grade histology. The role of BRAF V600E and
KRAS mutations in the classification of early stage colon
cancer is not well-defined. BRAF mutations were ob-
served in only 15 (4.9 %) of the patients in our study, so
no conclusions could have been made. In contrast,
KRAS mutations were detected much more frequently,
but no association with clinicopathological characteris-
tics was found.
The above genetic alterations have been extensively
examined by multiple groups for their possible prognos-
tic significance. The role of MMR status is in a large part
well-defined. It is generally accepted that dMMR confers
favorable prognosis in patients with resected colon can-
cer [19–23] and thus patients with stage II dMMR
Fig. 3 Forest plots demonstrating the multivariate analysis of prognostic factors for DFS and OS, including the interaction between MMR protein
status and primary tumor location. MMR protein status significantly interacted with primary site only for OS and not for DFS. Position at the right
side of the bar indicates adverse prognostic significance, whereas the opposite is consistent with favorable outcome. HR, hazard ratio; CI, confidence
interval; DFS, disease-free survival; OS, overall survival; pMMR, proficient mismatch repair; dMMR, deficient mismatch repair
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therapy. However, the role of MMR status in the treat-
ment of stage III disease remains controversial. Recently,
two large relevant studies have been published [24, 25].
In the study of Sinicrope et al. [24], MMR status was
not found to be prognostic in patients with resected
stage III colon cancer, probably due to interaction with
primary tumor site. Specifically, although dMMR con-
ferred favorable prognosis in right-sided tumors, it hadthe opposite role in the left colon. These findings were
confirmed by the present study, however the small sam-
ple size did not allow us to reach strong statistical sig-
nificance. In contrast, very recently, Klingbiel et al. [25]
showed that MSI high status is associated with pro-
longed relapse-free survival, irrespectively of the primary
site. No doubt, large validation series are needed to ob-
tain definitive answers to this question. The prognostic
role of KRAS mutations in resectable colon cancer
Pectasides et al. BMC Cancer  (2015) 15:384 Page 10 of 11remains until now controversial [25–31]. Sinicrope et al.
[24, 30] found that KRAS mutations were associated
with adverse prognosis specifically in pMMR tumors,
while Blons et al. [31] showed that KRAS mutations con-
ferred shorter DFS in patients with left colon primaries,
which seem to be consistent with our findings. An inter-
esting finding was also that anemia at presentation con-
ferred a better outcome. Although this was shown in the
multivariate analysis for DFS and OS, a plausible explan-
ation would be that other as yet unidentified confounding
factors, associated with favorable tumor biology, might
have been associated with anemia in our study population.
Conclusions
The present randomized clinical trial showed that
mFOLFOX6 and CAPOX are equally effective as adju-
vant treatments in patients with resected high-risk stage
II or III colorectal cancer and are equivalent therapeutic
options, justified by the generated evidence. The distinct
toxicity profiles, along with patient preferences and co-
morbidities, should guide the choice of therapy.
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